# US 2022/0008448 A1 · Methods of treating flt3-mutated hematologic cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008448 A1
- Document ID: US20220008448A1
- Status: Published application
- Kind: A1
- Application number: 17/282,170
- Filed: 2019-10-01
- Published: 2022-01-13
- Earliest claimed: 2018-10-01
- Applicants: Cti Biopharma Corp.; Ohio State Innovation Foundation
- Inventors: Bhavana BHATNAGAR; Sharyn D. BAKER
- Web page: https://patentgrep.com/patent/US20220008448A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/529: forming part of bridged ring systems
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods to inhibit FLT3 activity in a subject or a cell with an FLT3 mutation are provided. Methods of treating a hematologic cancer, such as acute myeloid leukemia, in a subject identified as having an FLT3 mutation, are also provided.

## Claims

### Claim 1

A method for treating a hematologic cancer, the method comprising:
administering an effective amount of a therapeutic agent having inhibitory activity against Janus kinase 2 (JAK2) and fms-like tyrosine kinase 3 (FLT3) to a subject having a predetermined genetic profile comprising an FLT3 mutation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the FLT3 mutation comprises an internal tandem duplication (ITD) mutation.

### Claim 3 (depends on 1)

The method of claim 1, wherein the FLT3 mutation comprises a tyrosine kinase domain (TKD) mutation.

### Claim 4 (depends on 3)

The method of claim 3, wherein the TKD mutation is a FLT 835 mutation.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 3)

The method of claim 3, wherein the TKD mutation comprises an FLT3 691 mutation.

### Claim at position 7

8-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the FLT3 mutation comprises ITD-835H, ITD-835V, ITD-D835Y, or ITD-F691L.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the therapeutic agent is pacritinib, or a pharmaceutically acceptable salt, prodrug, or N-oxide thereof.

### Claim at position 11

13-15. (canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the method further comprises administering an effective amount of a nucleoside analog, an intercalating agent, a hypomethylating agent, or combinations thereof.

### Claim at position 13

17-18. (canceled)

### Claim 19 (depends on 16)

The method of claim 16, wherein the nucleoside analog comprises cytarabine.

### Claim 20 (depends on 16)

The method of claim 16, wherein the intercalating agent comprises daunorubicin.

### Claim 21

(canceled)

### Claim 22 (depends on 16)

The method of claim 16, wherein the hypomethylating agent comprises decitabine or azacytidine.

### Claim 23 (depends on 1)

The method of claim 1, wherein the hematologic cancer comprises acute myeloid leukemia.

### Claim 24

(canceled)

### Claim 25

A method for treating acute myeloid leukemia, the method comprising:
administering an effective amount of pacritinib, or a pharmaceutically acceptable salt, prodrug, or N-oxide thereof to a subject having a predetermined mutation in FLT3, the mutation comprising:
i. an internal tandem duplication (ITD) mutation; and/or
ii. a tyrosine kinase domain (TKD) mutation.

### Claim 26 (depends on 25)

The method of claim 25, wherein the FLT3 mutation comprises an ITD mutation and a TKD mutation.

### Claim at position 22

27-36. (canceled)

### Claim 37 (depends on 25)

The method of claim 25, wherein the method further comprises administering an effective amount of a nucleoside analog, an intercalating agent, a hypomethylating agent, or combinations thereof.

### Claim at position 24

38-43. (canceled)

### Claim 44 (depends on 25)

The method of claim 25, wherein the acute myeloid leukemia is relapsed or refractory acute myeloid leukemia.

### Claim 45

A method of selecting a treatment regimen for a subject in need of treatment for a hematologic cancer, the method comprising:
receiving a genetic profile for the subject, the genetic profile comprising an FLT3 mutation; and
selecting a treatment regimen based on the genetic profile, the treatment regimen comprising a therapeutic agent having inhibitory activity against Janus kinase 2 (JAK2) and fms-like tyrosine kinase 3 (FLT3).

### Claim 46

(canceled)

### Claim 47 (depends on 45)

The method of claim 45, wherein the FLT3 mutation is a tyrosine kinase domain (TKD) mutation.

### Claim at position 29

48-55. (canceled)

### Claim 56 (depends on 45)

The method of claim 45, wherein the therapeutic agent is pacritinib, or a pharmaceutically acceptable salt, prodrug, or N-oxide thereof.

### Claim at position 31

57-61. (canceled)

### Claim 62 (depends on 45)

The method of claim 45, wherein the treatment regimen further comprises administering a nucleoside analog, an intercalating agent, a hypomethylating agent, or combinations thereof.

### Claim at position 33

63-68. (canceled)

### Claim 69 (depends on 45)

The method of claim 45, wherein the hematologic cancer comprises acute myeloid leukemia.

### Claim at position 35

70-80. (canceled)
